Navidea Biopharmaceutical... (NAVB)
0.00
-0.00 (-100.00%)
At close: Feb 27, 2025, 3:00 PM
0.00
11.11%
Pre-market: Sep 03, 2024, 09:30 AM EDT
Navidea Biopharmaceuticals Inc. Revenue Breakdown
| Quarter | Dec 31, 2022 | Sep 30, 2022 | Dec 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Mar 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Corporate Segment Revenue | 0 | 7.52K | 50.35K | 188.93K | 113.5K | 8.92K | 74.14K | 94.41K | 5.5K | 315.14K | 210.48K | 518.38K | 571.36K | 10.28M | 6.45M | 5.66M | 8.24M | 5.01M | 0 | 0 |
| Corporate Segment Revenue Growth | -100.00% | -85.07% | -73.35% | +66.45% | +1172.44% | -87.97% | -21.47% | +1614.95% | -98.25% | +49.73% | -59.40% | -9.27% | -94.44% | +59.32% | +13.99% | -31.31% | +64.67% | n/a | n/a | n/a |
| Diagnostics Segment Revenue | 610 | 0 | 0 | 30.32K | 154.89K | n/a | 82.14K | 39.14K | 44.11K | 80K | 13.19K | 93.22K | 8.67K | 20.69K | 102.9K | n/a | n/a | n/a | 0 | 0 |
| Diagnostics Segment Revenue Growth | n/a | n/a | -100.00% | -80.42% | n/a | n/a | +109.84% | -11.27% | -44.86% | +506.50% | -85.85% | +975.50% | -58.11% | -79.89% | n/a | n/a | n/a | n/a | n/a | n/a |
| Therapeutics Segment Revenue | 0 | 0 | 0 | n/a | n/a | n/a | n/a | 2.48K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Therapeutics Segment Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
| Quarter | Dec 31, 2015 |
|---|---|
| Non Us Revenue | 24.69K |
| Non Us Revenue Growth | n/a |
| U S Revenue | 10.23M |
| U S Revenue Growth | n/a |
Operating Expense Breakdown
| Quarter | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 1.3M | 1.32M | 1.15M | 1.26M | 3.64M | 1.26M | 1.81M | 2.32M | 1.47M | 1.43M | 2.23M | 1.75M | 1.79M | 1.33M | 1.83M | 1.17M | 1.52M | 1.86M | 1.82M | 1.44M | 2.69M | 1.79M | 1.78M | 2.16M | 1.73M | 4.25M | 3.02M | 3.09M | 2.94M | 2.89M | 4.1M | 3.77M | 3.94M | 4.05M | 5.49M |
| Selling, General, and Administrative Revenue Growth | -1.49% | +14.42% | -8.24% | -65.40% | +189.68% | -30.63% | -21.89% | +57.71% | +2.57% | -35.78% | +27.57% | -2.25% | +34.55% | -27.26% | +56.78% | -23.28% | -18.38% | +2.12% | +26.27% | -46.31% | +50.26% | +0.73% | -17.88% | +24.70% | -59.18% | +40.60% | -2.12% | +5.01% | +1.82% | -29.50% | +8.61% | -4.33% | -2.62% | -26.31% | n/a |
| Research and Development Revenue | 829.61K | 1.11M | 1.27M | 1.89M | 1.19M | 1.72M | 1.17M | 1.37M | 1.05M | 1.5M | 1.22M | 1.27M | 1.38M | 1.28M | 999.27K | 1.73M | 1.8M | 1.07M | 740.58K | 854.44K | 1.23M | 1.14M | 998.96K | 1.75M | 874.55K | 1.19M | 705.27K | 2.42M | 1.28M | 2.53M | 2.66M | 2.61M | 3.9M | 2.3M | 3.98M |
| Research and Development Revenue Growth | -25.01% | -12.72% | -32.94% | +59.31% | -31.18% | +47.44% | -14.80% | +30.85% | -29.99% | +22.51% | -3.81% | -7.75% | +7.51% | +28.27% | -42.09% | -4.22% | +68.27% | +44.57% | -13.33% | -30.29% | +7.27% | +14.39% | -42.86% | +99.89% | -26.25% | +68.14% | -70.87% | +89.76% | -49.47% | -5.04% | +2.01% | -33.19% | +69.88% | -42.30% | n/a |